A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases (ENTHUSE M1)

Clinical Trial ID NCT00554229

Rank	Title	Journal	Year	PubWeight™‹?›
1	G protein-coupled receptors: novel targets for drug discovery in cancer.	Nat Rev Drug Discov	2011	3.31
2	Bone metastasis in prostate cancer: emerging therapeutic strategies.	Nat Rev Clin Oncol	2011	2.20
3	Drug resistance in metastatic castration-resistant prostate cancer.	Nat Rev Clin Oncol	2010	1.86
4	Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.	Oncologist	2010	1.72
5	Emerging therapies to prevent skeletal morbidity in men with prostate cancer.	J Clin Oncol	2011	1.31
6	Emerging novel therapies in the treatment of castrate-resistant prostate cancer.	Can Urol Assoc J	2011	1.04
7	Update on options for treatment of metastatic castration-resistant prostate cancer.	Onco Targets Ther	2010	1.00
8	The changing landscape in the treatment of metastatic castration-resistant prostate cancer.	Ther Adv Med Oncol	2013	0.97
9	Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.	Int J Mol Sci	2013	0.88
10	Emerging targeted therapies for castration-resistant prostate cancer.	Front Endocrinol (Lausanne)	2012	0.81
11	Research in castration-resistant prostate cancer: what does the future hold?	Curr Oncol	2010	0.79
12	Synthesis and anticancer activity of N-aryl-5-substituted-1,3,4-oxadiazol-2-amine analogues.	Biomed Res Int	2014	0.75
13	Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?	Int J Mol Sci	2016	0.75